⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

March 23, 2026Arthritis & Rheumatology

Subsets of Lupus Patients Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib

Prathyusha Bachali Amrie C. Grammer Peter E. Lipsky

View at Publisher

Ask AI

Bookmark

Share

Key Points

The research aims to identify specific subsets of lupus patients based on their gene expression profiles and their response to baricitinib treatment.
Conducted transcriptomic analysis of SLE patient samples
Identified gene expression profiles grouping patients
Evaluated clinical responsiveness to baricitinib in identified subsets
Distinct subsets of SLE patients were identified based on gene expression profiles
Certain subsets showed improved clinical responsiveness to baricitinib treatment

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Transcriptomic analysis identifies lupus subsets responsive to baricitinib, suggesting tailored treatments.

Abstract

Transcriptomic analysis identified SLE patient subsets responsive to baricitinib.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bachali et al. (2026) studied this question.

synapsesocial.com/papers/69c37bd4b34aaaeb1a67e9fc https://doi.org/10.1002/art.70130

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1O13 Innate immunity transcriptional profiles as potential predictive biomarkers for treatment response in systemic lupus erythematosus: Insights from a longitudinal study2024
2A double‐blind pilot study of oral baricitinib in adult patients with lupus erythematosus panniculitis2024 · 5 citations
3The effect of baricitinib on pSTAT3 levels in IL-6- or IL-15-stimulated PBMCs isolated from patients with SLEOriginal Research · 2025 · 3 citations
4Systemic lupus erythematosus patients contain B‐cell receptor repertoires sensitive to immunosuppressive drugsOriginal Research · 2022 · 16 citations
5Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysisLate-Phase Clinical Trial · 2023 · 9 citations
6Molecular characterisation of telitacicept response phenotypes in systemic lupus erythematosus: an exploratory integrated transcriptome and B-cell receptor repertoire profiling studyLongitudinal Study · 2026
7P157 Baricitinib for the treatment of Rhupus Syndrome2024 · 4 citations
8Significance of miRNA Profile of Regulatory T Cells (Tregs) After Baricitinib Treatment in Rheumatoid Arthritis Patients2025 · 2 citations
9Predicting Inactive Disease in Juvenile Idiopathic Arthritis: A Dynamic Machine Learning ApproachArthritis & Rheumatology · 2026
10Hypogammaglobulinemia in Patients With Inflammatory Rheumatic Diseases Treated With IL-6 Receptor Inhibitors: A Retrospective Comparative Cohort Study.Arthritis & Rheumatology · 2026

More from Arthritis & Rheumatology

More from Ampel BioSolutions (United States)